Pharmacologic bridging with prostaglandin E1 before heart transplantation - A new chance for an old drug

Journal of Clinical and Basic Cardiology

Volumn 5, Issue 2, 2002, Pages 171-177

  Stanek, Brigitte ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bridging therapy; Heart transplantation; Outcome; Prostaglandin E1; Refractory heart failure

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; PROSTACYCLIN; PROSTAGLANDIN E1; VASODILATOR AGENT;

ADULT; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 0036330378     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Isolation of prostaglandin E1 from human seminal plasma
2. Cardiovascular effects of prostaglandin E
3. Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems
4. The investigation of prostaglandin action
5. Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension
6. Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease
7. Prostaglandin E1: A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement
8. Prostaglandin E1 for refractory right heart failure after coronary artery bypass grafting
9. Successful treatment of acute postoperative right heart failure with low-dose prostaglandin E1 and assisted circulation
10. Cardiocirculatory and myocardial energetic effects of prostaglandin E1 in severe left ventricular failure due to chronic coronary disease
11. Haemodynamic effects of prostaglandin E1 infusion in patients with acute myocardial infarction and left ventricular failure
12. Effects of prostaglandin E1 on haemodynamics and blood gases in severe left heart failure
13. Femoral artery infusion of prostaglandin E1 in severe peripheral vascular disease
14. Prostaglandin E1
15. Prostaglandin E-1: An effective treatment of right heart failure after orthotopic heart transplantation
16. Prostaglandin E1 for treatment of elevated pulmonary vascular resistance in patients undergoing cardiac transplantation
17. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension
18. Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation
19. Prostaglandin E1 induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation
20. Eingeladener kommentar (zu H Müller transplantevaluation und therapie mit prostaglandin E1 bei patienten mit erhöhtern lungenwiderstand)
21. Prostaglandin E1 in heart failure: The Vienna experience
22. Beneficial haemodynamic effects of prostaglandin E1 infusion in catecholamine-dependent heart failure: Results of a prospective, randomized, controlled study
23. Effect of prostaglandin E1 infusion in severe chronic heart failure
24. Prostaglandin E1 and nitroglycerine in severe dilated cardiomyopathy. Results from combined haemodynamic, magnetic resonance imaging and neurohumoral evaluation
25. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure
26. Combined haemodynamic echocardiographic Doppler evaluation of prostaglandin E1 effects in patients with severe dilated cardiomyopathy undergoing evaluation for heart transplantation
27. Dose-effect-relationships of PGE1 in severe endstage heart failure
28. Ambulatory vasodilator therapy in heart failure: Systematic review of the literature and personal observational experience
29. Prostaglandin E1-bridge to cardiac transplantation: Technique, dosage, results
30. Hemodynamic and neurohumoral effects of long-term PGE1 infusions in outpatients with severe congestive heart failure
31. Effects of continuous, long-term therapy with prostaglandin E1 preoperatively on outcome after heart transplantation
32. Response of right ventricular function to prostaglandin E1 infusion predicts outcome for severe chronic heart failure patients awaiting urgent transplantation
33. Bridging to heart transplantation: Prostaglandin E1 versus prostacyclin versus dobutamine
34. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure
35. PGE1 infusion compared with prostacyclin infusion in patients with refractory heart failure. Effects on hemodynamics and neurohumoral variables
36. Hemodynamic studies with prostaglandin E1 as compared with dobutamine in severe chronic heart failure
37. Prognostic value of hemodynamic versus big endothelin measurements during chronic intravenous therapy in advanced heart failure patients
38. Pulmonary hypertension in severe congestive heart failure: How important is it?
39. Plasma prostaglandin E1 concentrations and haemodynamics during intravenous infusions of prostaglandin E1 in humans and swine
40. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin
41. Regulatory mechanism of the vascular endothelium: An update
42. Basic mechanism of prostaglandin action on autonomic neurotransmission
43. Moderation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney
44. Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear
45. Potential use of prostaglandin E1 analog for cardiovascular disease
46. Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E1
47. Analysis and predictors of pulmonary vascular resistance after cardiac transplantation
48. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover
49. Right ventricular diastolic dysfunction in heart failure
50. Right ventricular performance and contractile reserve in patients with severe heart failure
51. ACE inhibitor dosage at the time of listing predicts survival
52. Experience with β-blocker therapy in patients with advanced heart failure evaluated for HTx
53. Optimising management of patients with advanced heart failure: The importance of preventing progression
54. Acceptance of a pump-driven infusiion therapy with prostaglandin E1 as a bridge to heart transplantation
55. Combined oral positive inotropic and β-blocker therapy for treatment of refractory class IV heart failure
56. Phosphodiesterase inhibitors in refractory heart failure: Bridge to beta-blockade?
57. Intravenous therapy for advanced heart failure